DeepQure Unveils Promising Clinical Results at AUA 2026 for Groundbreaking RDN System
Promising Developments in Renal Denervation at AUA 2026
In an exciting presentation at the American Urological Association (AUA) Innovation Nexus Forum, DeepQure, a pioneering clinical-stage medical device company, unveiled promising results from their innovative HyperQure™ – the world’s first minimally invasive extravascular renal denervation (RDN) system. This presentation highlighted the company’s ongoing clinical progress in addressing uncontrolled hypertension, a pressing global health issue affecting approximately 30% of hypertensive patients worldwide.
A New Approach to Uncontrolled Hypertension
Traditional catheter-based intravascular RDN methods face significant challenges due to their dependence on vessel anatomy, which can lead to incomplete or inconsistent nerve ablation. As a result, many patients experience variable blood pressure reduction. In response to these limitations, HyperQure™ has been specifically designed to enable direct, circumferential ablation of the perivascular nerves from outside the artery, enhancing the effectiveness of treatment regardless of individual vessel architecture.
DeepQure’s emphasis on innovation positions it uniquely within the industry, as the company aims to bridge the
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.